Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

Recruiting now · Not applicable

Conditions studied: Kidney Transplant Rejection

In brief

Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR). Annually, 5000 kidney transplants are lost in the United States due to CAMR. The two-year graft survival rate in CAMR is approximately 20%, highlighting the need for a more efficient therapy for CAMR and directly targeting donor specific antibody (DSA) producing cells and reducing CAMRThere is no established treatment for this problem. While many centers intensify and optimize the dosage of immunosuppressive drugs, treatments such as plasmapheresis, IVIG, and rituximab, although effective in treating AMR, have not been successful in reducing DSA or improving kidney graft survival in CAMR patients. Despite these treatments, two-year graft survival can increase up to 55%. The use of anti-plasma cell treatments like bortezomib has also yielded inconsistent results.

Key facts

Study ID

NCT07006532

Run by

Shahid Beheshti University of Medical Sciences

People needed

50

Starts

2025-01-01

Expected to finish

2027-05-01

Last updated by the study team

2026-02-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed written informed consent
• eGFR> 25 cc/min
• Chronicity index <8
• IFTA<40%
• EBV IgG positive

You may not qualify if…

• Active or recurrent infections
• History of malignancy, unless in remission for more than 2 years with no relapse
• abnormal liver function tests
• Platelet < 100,000

Where it is running

• Nooshin Dalili — Tehran, Iran (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.